Search - tctmd.com

Displaying 221 - 240 of 716

Sort: Relevancy | Date

Presentation THT 2023

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre Cardiogenic Shock

Presenter: Gad Cotter

March 22, 2023

Presentation THT 2023

Does Obesity Paradox Exist in Cardiogenic Shock?

Presenter: Maya Guglin

March 22, 2023

Presentation THT 2023

Pulmonary Artery Catheter Use in Patients with Heart Failure Cardiogenic Shock (HF-CS): An Analysis from the Cardiogenic Shock Working Group (CSWG)

Presenter: Adnan Khalif

March 21, 2023

Presentation THT 2023

Initial Results From the Early Feasibility Study of the Edwards Left Atrial to Coronary Sinus Apture Transcatheter Shunt System

Presenter: William Gray

March 21, 2023

Presentation THT 2023

Cardiogenic Shock With MCS and Review of Shock Algorithm

Presenter: Raymond Yau

March 21, 2023

Presentation THT 2023

Assessing RV Function in Cardiogenic Shock: When to Pull the Trigger on MCS

Presenter: Arthur Reshad Garan

March 21, 2023

Presentation THT 2023

BPA in CTEPH Management

Presenter: Kenneth Rosenfield

March 21, 2023

Presentation THT 2023

Heart Team Decision: CABG

Presenter: NULL

March 20, 2023

Presentation THT 2023

Heart Team Decision: Protected PCI

Presenter: Rhian Davies

March 20, 2023

Presentation THT 2023

Heart Team Decision: Revascularization vs Medical Management

Presenter: Anuradha Lala-Trindade

March 20, 2023

Presentation THT 2023

CAD is Underdiagnosed

Presenter: James Januzzi

March 20, 2023

News Conference News THT 2023

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

Todd Neale

March 20, 2023

Presentation THT 2023

LA to Coronary Sinus: The Edwards APTURE Shunt

Presenter: William Gray

March 20, 2023

Presentation THT 2023

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

Presenter: Graham Nichol

March 20, 2023

Presentation THT 2023

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Mauro Moscucci

March 20, 2023

Presentation THT 2023

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

Presenter: Song Li

March 20, 2023

Presentation THT 2023

Biomarkers and Risk Stratification for Cardiogenic Shock

Presenter: Ajar Kochar

March 20, 2023

Presentation THT 2023

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Presenter: David Baran

March 20, 2023

Advertisement

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre Cardiogenic Shock

Does Obesity Paradox Exist in Cardiogenic Shock?

Pulmonary Artery Catheter Use in Patients with Heart Failure Cardiogenic Shock (HF-CS): An Analysis from the Cardiogenic Shock Working Group (CSWG)

Initial Results From the Early Feasibility Study of the Edwards Left Atrial to Coronary Sinus Apture Transcatheter Shunt System

Cardiogenic Shock With MCS and Review of Shock Algorithm

Assessing RV Function in Cardiogenic Shock: When to Pull the Trigger on MCS

BPA in CTEPH Management

Heart Team Decision: CABG

Heart Team Decision: Protected PCI

Heart Team Decision: Revascularization vs Medical Management

CAD is Underdiagnosed

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

LA to Coronary Sinus: The Edwards APTURE Shunt

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

FDA Introduction

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

Biomarkers and Risk Stratification for Cardiogenic Shock

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content